Abstract
Substance use disorders (SUDs) among women with gynecologic cancers pose challenges to treatment adherence, patient well-being, morbidity, and mortality. Despite the prevalence of SUDs, routine screening practices have not been widely adopted. This quality improvement project implemented the Revised Opioid Risk Tool (ORT-OUD) to screen for SUDs among gynecologic oncology patients. The aims were to provide a referral to addiction psychiatry in a minimum of 80% of patients who screened as high risk and demonstrate the feasibility of ORT-OUD implementation in clinical practice, with at least 75% of advanced practice providers (APPs) reporting it as feasible. The ORT-OUD was offered to all patients aged 18 years or older, consented, and were on the APPs’ schedules during the project implementation period (3 months). Patients completed the ORT-OUD privately, and APPs reviewed and scored the tool. Patients with scores of 3 or higher were offered a referral to addiction psychiatry. Advanced practice providers were then given a survey to assess their perception of the project’s feasibility. Descriptive statistics were used to track referral rates and APP perceptions. Of 134 patients screened, 9.7% were identified as high risk for SUDs. Of those patients, 76.9% accepted a referral to addiction psychiatry. One hundred percent of APPs reported the ORT-OUD implementation as feasible. Challenges identified included time needed to explain the screening tool and patients’ perceptions of the screening tool questions. This project successfully identified a proportion of gynecologic oncology patients at risk for SUDs and facilitated access to specialized care. Challenges in the screening process highlight the importance of patient education and communication strategies.
References
Aldridge, A., Linford, R., & Bray, J. (2017). Substance use outcomes of patients served by a large U.S. implementation of screening, brief intervention, and referral to treatment (SBIRT). Society for the Study of Addiction, 112(52), 43–53. https://doi.org/10.1111/add.13651
Barclay, J. S., Owens, J. E., & Blackhall, L. J. (2014). Screening for substance abuse risk in cancer patients using the Opioid Risk Tool and urine drug screen. Supportive Care in Cancer, 22(7), 1883–1888. https://doi.org/10.1007/s00520-014-2167-6
Carmichael, A. N., Morgan, L., & Del Fabbro, E. (2016). Identifying and assessing the risk of opioid abuse in patients with cancer: An integrative review. Substance Abuse and Rehabilitation, 71–79. https://doi.org/10.2147/SAR.S85409
Cheatle, M. D., Compton, P. A., Dhingra, L., Wasser, T. E., & O’Brien, C. P. (2019). Development of the revised opioid risk tool to predict opioid use disorder in patients with chronic nonmalignant pain. The Journal of Pain, 20(7), 842–851. https://doi.org/10.1016/j.jpain.2019.01.011
Choflet, A., Hoofring, L., Cheng, Z., Katulis, L., Narang, A., & Appling, S. (2020). Substance use screening protocol: Implementation of a system for patients with cancer. Clinical Journal of Oncology Nursing, 24(5), 554–560. https://doi.org/10.1188/20.cjon.554-560
Coffa, D., & Snyder, H. (2019). Opioid use disorder: Medical treatment options. American Family Physician, 100(7), 416–425. https://www.aafp.org/pubs/afp/issues/2019/1001/p416.html
Dannenberg, M. D., Bruce, M. L., Barr, P. J., & Broglio, K. (2022). Prevalence of opioid misuse risk in patients with cancer. Clinical Journal of Oncology Nursing, 26(3), 261–267. https://doi.org/10.1188/22.CJON.261-267
Farkouh, A., Riedl, T., Gottardi, R., Czejka, M., & Kautzky-Willer, A. (2020). Sex-related differences in pharmacokinetics and pharmacodynamics of frequently prescribed drugs: A review of the literature. Advances in Therapy, 37(2), 644–655. https://doi.org/10.1007/s12325-019-01201-3
Goetz, T. G., Becker, J. B., & Mazure, C. M. (2021). Women, opioid use and addiction. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 35(2), e21303. https://doi.org/10.1096/fj.202002125R
Lefkowits, C., & Duska, L. (2017). Opioid use in gynecologic oncology; Balancing efficacy, accessibility and safety: An SGO Clinical Practice Statement. Gynecologic Oncology, 144(2), 232–234. https://doi.org/10.1016/j.ygyno.2016.11.015
McLellan, A. T. (2017). Substance misuse and substance use disorders: Why do they matter in healthcare? Transactions of the American Clinical and Climatological Association, 128, 112. https://pmc.ncbi.nlm.nih.gov/articles/PMC5525418/
Ramzan, A. A., Fischer, S., Buss, M. K., Urban, R. R., Patsner, B., Duska, L. R., Fisher, C. M., & Lefkowits, C. (2018). Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II - Balancing safety & accessibility. Gynecologic Oncology, 149(2), 401–409. https://doi.org/10.1016/j.ygyno.2018.02.008
Snijders, R. A., Brom, L., Theunissen, M., & van den Beuken-van Everdingen, M. H. (2023). Update on prevalence of pain in patients with cancer 2022: A systematic literature review and meta-analysis. Cancers, 15(3), 591. https://doi.org/10.3390/cancers15030591
Strand, M. A., Eukel, H. N., Frenzel, O., Skoy, E., Steig, J., & Werremeyer, A. (2022). Opioid risk stratification in the community pharmacy: The utility of the opioid risk tool. Research in Social and Administrative Pharmacy, 18(12), 4065–4071. https://doi.org/10.1016/j.sapharm.2022.07.009
Substance Abuse and Mental Health Services Administration. (2015). Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf
Teulings, L. & Broglio, K. (2020). Opioid misuse risk: Implementing screening protocols in an ambulatory oncology clinic. Clinical Journal of Oncology Nursing, 24(1), 11–14. https://doi.org/10.1188/20.CJON.11-14
Yusufov, M., Braun, I. M., & Pirl, W. F. (2019). A systematic review of substance use and substance use disorders in patients with cancer. General Hospital Psychiatry, 112Override-8"> https://doi.org/10.1016/j.genhosppsych.2019.04.016
